Aptus Pharma Limited has announced its strategic entry into the Urology therapy segment as part of its ongoing business expansion initiatives.

The company will soon be launching a new portfolio of products in this segment, including: Silodosin range, Tamsulosin range and Alkalizer formulations.

The introduction of these products is supported by the Company's strong field-sales force and a robust distribution network consisting of 150+ PLS distributors and sub-distributors across India. This new portfolio is expected to contribute significantly to the Company's future revenue growth and profitability.

The Indian urology market is one of the fastest-growing chronic therapy segments, currently expanding at approximately 9-10% annually.

Commenting on this development, Tejash Hathi, Managing Director, Aptus Pharma Limited., stated: "Our entry into the urology therapy segment further strengthens our specialty-care capabilities and positions the Company for sustained growth in the coming years."